<?xml version="1.0" encoding="UTF-8"?>
<p>With the publication of the RNA genome sequence of SARS‐CoV‐2 (GenBank: MN908947), one strategy could aim to target the viral RNA genome itself for degradation, in addition to targeting the surface proteins and viral replicases. Therefore, using small interfering RNAs (siRNAs), RNA aptamers or antisense oligonucleotides (ASOs) against the SARS‐CoV RNA genome may provide important insights and promising therapeutic targets for SARS‐CoV‐2 treatment (Ahn et al., 
 <xref rid="bph15092-bib-0004" ref-type="ref">2009</xref>; Asha et al., 
 <xref rid="bph15092-bib-0008" ref-type="ref">2018</xref>; Qureshi, Tantray, Kirmani, &amp; Ahangar, 
 <xref rid="bph15092-bib-0078" ref-type="ref">2018</xref>; Shum &amp; Tanner, 
 <xref rid="bph15092-bib-0085" ref-type="ref">2008</xref>).
</p>
